The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 601–700 of 998
An H3F3A K27M‐mutation in a sonic hedgehog medulloblastoma
Dottermusch, M., Uksul, N., Knappe, U. J., Erdlenbruch, B., & Wefers, A. K. (2021) · Brain Pathology · doi:10.1111/bpa.13024 · Cited by 9
“Large series of SHH medulloblastomas have been sequenced to date to analyse the mutational spectrum [1, 2].”
BackgroundSignificance of DNA methylation assessment in the morphological diagnosis of brain tumours
Ryzhova, M. V., Galstyan, S. A., & Телышева, Е. Н. (2022) · Russian Journal of Archive of Pathology · doi:10.17116/patol20228403165 · Cited by 10
Self-citationSavini, C., Yang, R., Savelyeva, L., Göckel-Krzikalla, E., Hotz‐Wagenblatt, A., Westermann, F., & Rösl, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051100 · Cited by 8
SMARCA4 Loss and Mutated β-Catenin Induce Proliferative Lesions in the Murine Embryonic Cerebellum
Göbel, C., Schoof, M., Holdhof, D., Spohn, M., & Schüller, U. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1605-23.2024 · Cited by 7
Monteiro, J. M., Dalmolin, M., Fernandes, M. A. C., Ramos, J. I. R., Ribas, C. A. P. M., Tabushi, F. I., Roesler, R., & Isolan, G. R. (2024) · Brain Sciences · doi:10.3390/brainsci14111146 · Cited by 7
“MB is currently classified into four consensus molecular subgroups, namely wingless-activated (WNT), sonic hedgehog (SHH), Group 3, and Group 4, with Group 3 MB being particularly associated with poorer survival and metastasis [13–15].”
Developmental Origins and Oncogenesis in Medulloblastoma
Kiang, K. M. Y., Wong, Y. K. H., Sengupta, S., Roussel, M. F., & Lu, Q. R. (2025) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-112723-061540 · Cited by 11
SNUH methylation classifier for CNS tumors
Lee, K.-H., Jeon, J., Park, J. W., Yu, S., Won, J., Kim, K., Park, C., & Park, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01824-0 · Cited by 7
Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival
Talbot, J., Fombonne, J., Torrejon-Diaz, J., Babcock, B. R., McSwain, L., Rama, N., Severini, L. L., Bonerandi, E., Marsaud, V., Bernardi, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59612-6 · Cited by 8
Arora, S., Nuechterlein, N., Jensen, M., Glatzer, G., Sievers, P., Varadharajan, S., Korshunov, A., Sahm, F., Mack, S. C., Taylor, M. D., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf251 · Cited by 11
Self-citationBernardi, F., Torrejon-Diaz, J., Basili, I., Ommeren, R. V., Marsaud, V., Yu, H., Talbot, J., Souphron, J., Indersie, É., Forget, A., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.012 · Cited by 11
Self-citationClinical and Molecular Features in Medulloblastomas Subtypes in Children in a Cohort in Taiwan
Wu, K.-S., Sung, S., Huang, M., Lin, Y., Chang, C., Fang, C., Wong, T., Chen, H., & Tsai, M. (2022) · Cancers · doi:10.3390/cancers14215419 · Cited by 8
“Northcott and colleagues identified eight subtypes (I to VIII) in non-WNT/non-SHH MBs, which were recruited in the 2021 WHO CNS5 classification [3,4].”
BackgroundSelf-citationLiserre, R., Branzoli, F., Pagani, F., Gryzik, M., Cominelli, M., Miele, E., Marjańska, M., Doglietto, F., & Poliani, P. L. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01531-y · Cited by 9
“IDH mutations in MB are rarely reported and not routinely investigated [20].”
BackgroundBrain and Spinal Cord Tumors of Embryonic Origin
Lampros, M. G., & Alexiou, G. Α. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_15 · Cited by 7
Echavidre, W., Durivault, J., Gotorbe, C., Blanchard, T., Pagnuzzi, M., Vial, V., Raes, F., Broisat, A., Villeneuve, R., Amblard, R., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0298 · Cited by 9
Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma
Coulter, D. W., Chhonker, Y. S., Kumar, D., Kesherwani, V., Aldhafiri, W. N., McIntyre, E. M., Alexander, G. R., Ray, S., Joshi, S. S., Li, R., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02944-w · Cited by 7
“Of these, Group 3 MB often exhibits MYC amplification (17–20% of cases) or overexpression, metastasis (40–50% of cases), and treatment failure, and it has the worst prognosis of the MB subgroups with 60% survival [5, 8, 9].”
BackgroundAberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors
Pekkarinen, M., Nordfors, K., Uusi-Mäkelä, J., Kytölä, V., Hartewig, A., Huhtala, L., Rauhala, M. J., Urhonen, H., Häyrynen, S., Afyounian, E., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202302088 · Cited by 9
“Traditionally, researchers have compared and analyzed sub-types of AT/RTs, MBs, and PLEXs separately (Merino et al, 2015; Torchia et al, 2015; Johann et al, 2016; Northcott et al, 2017).”
Do, A. D., Wu, K.-S., Chu, S.-S., Giang, L. H., Lin, Y., Chang, C., Wong, T., Hsieh, C., & Sung, S. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03057-0 · Cited by 8
“Accounting for ∼ 30% of all MB cases, SHH-MB has an intermediate to good prognosis in children and a well-characterized molecular profile [3, 4, 8, 9].”
BackgroundSelf-citationA case of molecularly profiled extraneural medulloblastoma metastases in a child
Mobark, N. A., Alharbi, M., Mosleh, O., Santagata, S., Snuderl, M., & Abedalthagafi, M. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0526-8 · Cited by 9
“We used the previously described by the German Cancer Research Center (DKFZ), in-depth analysis of the DNA methylation [4, 5].”
Less treatment for Wing less medulloblastoma: germline data re-emphasize this
Das, A., & Ramaswamy, V. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz213 · Cited by 7
Self-citationY-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?
Taylor, L., Kerr, I. D., & Coyle, B. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0655 · Cited by 10
The multilayer community structure of medulloblastoma
Núñez‐Carpintero, I., Petrizzelli, M., Zinovyev, A. Y., Cirillo, D., & Valencia, A. (2021) · iScience · doi:10.1016/j.isci.2021.102365 · Cited by 9
Rajappa, P., Eng, K., Bareja, R., Bander, E. D., Yuan, M., Dua, A. N., Maachani, U. B., Snuderl, M., Pan, H., Zhang, T., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac031 · Cited by 7
López, C., Schleußner, N., Bernhart, S. H., Kleinheinz, K., Sungalee, S., Sczakiel, H. L., Kretzmer, H., Toprak, U. H., Glaser, S., Wagener, R., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280005 · Cited by 7
“27,28 To determine the incidence of structural variants in the PCWAG, fi ltered structural variant calls were generated by SOPHIA for the PCAWG cohorts processed with the same tools and settings as with the lymphoma cohort used in this study.”
Self-citationIdentification of PBK as a hub gene and potential therapeutic target for medulloblastoma
Deng, Y., Wen, H., Yang, H., Zhu, Z., Huang, Q., Bi, Y.-W., Wang, P., Zhou, M., Guan, J., Zhang, W., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8336 · Cited by 8
“Somatic CTNNB1 mutations and chromosome 6 loss are common in the WNT subgroup (4), while the amplifi‐ cation of GLI1 or GLI2 and the deletion of Patched 1 (PTCH1) are frequently observed in the SHH subgroup (5).”
BackgroundBecklin, K. L., Draper, G. M., Madden, R. A., Kluesner, M. G., Koga, T., Huang, M., Weiss, W. A., Spector, L. G., Largaespada, D. A., Moriarity, B. S., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0032 · Cited by 8
“73,74 To further investigate the phenotypic response to MYCN expression, iPSC and primary NES cells were transduced with a mutated MYCN T58A or MYCN WT lentivirus.”
Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts
Leskoske, K. L., Garcia‐Mansfield, K., Sharma, R., Krishnan, A., Rusert, J. M., Mesirov, J. P., Wechsler‐Reya, R. J., & Pirrotte, P. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00203 · Cited by 9
Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis
Cao, L., Zhao, Y., Liang, Z., Yang, J., Wang, J., Tian, S., Wang, Q., Wang, B., Zhao, H., Jiang, F., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.815260 · Cited by 7
“Considering the epigenetic disorders in pediatric brain tumors (Lin et al., 2016; Northcott et al., 2017; Petralia et al., 2020), we investigated the cause of MCM3 dysregulation at the methylation level.”
BackgroundKameda-Smith, M. M., Zhu, H., Luo, E.-C., Suk, Y., Xella, A., Yee, B., Chokshi, C., Xing, S., Tan, F., Fox, R. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35118-3 · Cited by 7
LIN28 expression and function in medulloblastoma
Maklad, A., Sedeeq, M., Wilson, R., Heath, J. A., Gueven, N., & Azimi, I. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30946 · Cited by 9
Moss, R. M., Sorajja, N., Mills, L. J., Moertel, C. L., Hoang, T. T., Spector, L. G., Largaespada, D. A., & Williams, L. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1113121 · Cited by 11
“Medulloblastoma is comprised of four main molecular subgroups (3) that are prognostic with sonic hedgehog (SHH), Group 3 and Group 4 tumors associated with worse prognoses than wingless (WNT) tumors (4).”
BackgroundRohrer, K., Song, H., Akbar, A., Chen, Y., Pramanik, S., Wilder, P. J., McIntyre, E. M., Chaturvedi, N. K., Bhakat, K. K., Rizzino, A., et al. (2023) · Cancers · doi:10.3390/cancers15082239 · Cited by 12
“Although current multimodal approaches in MB have significantly improved overall survival rates, high doses of cytotoxic chemotherapies are often associated with long-term toxicities, including neurocognitive impairments and ototoxicity in surviving patients [58,59].”
BackgroundMoreno, D. A., Bonatelli, M., Antoniazzi, A. P., de Paula, F. E., Leal, L. F., Garcia, F. A. D. O., de Paula, A. E., Teixeira, G. R., Santana, I. V. V., Saggioro, F. P., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1237170 · Cited by 8
“It included five different whole exome and genome datasets from the Pediatric Cancer Genome Project (PCGP) (whole genome, Nature 2012, n=37) (18), the Sickkids (whole genome, Nature 2016, n=46) (19), International Cancer Genome Consortium (ICGC) (whole exome, Nature 2012, n=125) (20), The German Cancer Research Center…”
de Estíbariz, I. M., Jakjimovska, A., Illarregi, U., Martín‐Guerrero, I., Gutiérrez-Camino, Á., López-López, E., & Bilbao‐Aldaiturriaga, N. (2023) · Cancers · doi:10.3390/cancers15194686 · Cited by 6
“These subgroups, considered the most aggressive, are classified into the HR group [8].”
BackgroundKatsushima, K., Joshi, K., Yuan, M., Romero, B., Batish, M., Stapleton, S. L., Jallo, G. I., Kolanthai, E., Seal, S., Saulnier, O., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113938 · Cited by 8
Self-citationMedulloblastoma in infants: the never-ending challenge
Lassaletta, Á. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30278-x · Cited by 7
New research directions in medulloblastoma
Grill, J., Dufour, C., Guerrini‐Rousseau, L., & Ayrault, O. (2019) · Neurochirurgie · doi:10.1016/j.neuchi.2019.01.002 · Cited by 7
A framework for mutational signature analysis based on DNA shape parameters
Karolak, A. M., Levatić, J., & Supek, F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262495 · Cited by 7
“The called mutations from cancer WGS were collected from: (i) The Cancer Genome Atlas (TCGA, https://www.cancer.gov/tcga), studies: BLCA, BRCA, CESC, COAD, DLBC, GBM, HNSC, KICH, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PRAD, READ, SARC, SKCM, STAD, THCA, UCEC; (ii) International Cancer Genome Consortium data portal (IC…”
MethodInfluentialEffective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1
Zhao, Y., Li, T., Tian, S., Meng, W., Sui, Y., Yang, J., Wang, B., Liang, Z., Zhao, H., Han, Y., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s278844 · Cited by 13
Dahl, N. A., Donson, A. M., Sanford, B. L., Wang, D., Walker, F. M., Gilani, A., Foreman, N. K., Tinkle, C. L., Baker, S. J., Hoffman, L. M., et al. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab016 · Cited by 7
Rausch, T., Snajder, R., Léger, A., Simovic-Lorenz, M., Stegle, O., Birney, E., Bonder, M. J., Ernst, A., & Korbel, J. O. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.20.480758 · Cited by 7
Self-citationHIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma
Contenti, J., Guo, Y., Larcher, M., Mirabal-Ortega, L., Rouleau, M., Irondelle, M., Tiroille, V., Mazzu, A., Duranton-Tanneur, V., Pedeutour, F., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02100-5 · Cited by 6
“Each subgroup is characterized by speci fi c genetic alterations, gene expression patterns, and signaling pathway dysregulations, which in fl uence tumor development, progression, and response to therapy [2 – 5].”
de Araújo, M. A., Malafaia, O., Ribas-Filho, J. M., Fratini, L., Roesler, R., & Isolan, G. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411601 · Cited by 9
“The database Tumor Medulloblastoma-Pfister-167 [5] was downloaded from R2: Genomics Analysis and Visualization Platform (https://hgserver1.amc.nl/cgi-bin/r2/main. cgi (accessed on 12 July 2023)).”
MethodResultInfluentialGou, P., Fang, C., Xu, M., Zhang, D., Wu, X., Zhang, L., Li, X., Li, M., Gan, L., Luo, J., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02470-4 · Cited by 9
“As one of the most common malignant brain tumors in children, the World Health Organization classi fi ed medulloblastoma (MB) into four subtypes on the basis of genomics and DNA methylation: WNT, SHH, and non-WNT/non-SHH (Group 3 and Group 4) [1, 2].”
Self-citationEZH2 inhibitor and Vismodegib synergistically inhibit the growth and metastasis of medulloblastoma
Xu, C., Wang, B., Xu, T., Lv, Y., Pan, X., Zhao, X., Tan, F., Sheng, H., & Yu, L. (2025) · Medical Oncology · doi:10.1007/s12032-025-02734-0 · Cited by 6
“To delve deeper into MB characteristics and address this issue of drug resistance, genomic sequencing of MB cases was undertaken [9].”
Kawata, K., Chapman, O. S., Narumi, S., & Kawauchi, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1569548 · Cited by 8
DeCarlo, A., MacLeod, G. D. A. H., da Silva, C. F., Shen, L., Povilaikaite, J., Deane, M., Aragao, L., Sie, M., Termini, D., Magee, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102202 · Cited by 6
Self-citationZhang, X., Chen, Q., Yang, M., Zhao, Z., Zheng, Y., Dai, Q., He, Y., Cai, D., & Xu, T. (2025) · IEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing · doi:10.1109/jstars.2025.3587241 · Cited by 8
“The DTW algorithm, proposed by Japanese scholar Itakura [69]in the 1960s, dynamically aligns two time series in the temporal domain to estimate the minimum possible distance between them [70].”
Mishra, D. K., Morris, S. M., Popovski, D., Girard, E. J., Bondoc, A., Kumar, S. S., Andrade, A. F., Zhu, X., Yao, F., Brusniak, M., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf241 · Cited by 9
Self-citationThe role of histone acetyltransferases in tumorigenesis and their therapeutic potential: A review
Lin, R., Zhang, Y., Li, H., & Liang, F. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153097 · Cited by 8
Morgacheva, D. A., Daks, A. A., Smirnova, А. Y., Kim, A., Рыжкова, Д. В., Mitrofanova, L. B., Staliarova, A., Omelina, E. S., Pindyurin, A. V., Fedorova, O., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.925340 · Cited by 7
Fang, H., Wang, L., Yu, L., Shen, F., Yang, Z., Yang, Y., Li, S., Dai, H., Tan, F., Lin, J. J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.928853 · Cited by 6
Genetic and Epigenetic Dysregulation of Transcriptional Enhancers in Cancer
Botten, G. A., & Xu, J. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060324-114306 · Cited by 9
Sollier, E., Riedel, A., Toprak, U. H., Wierzbińska, J. A., Weichenhan, D., Schmid, J. P., Hakobyan, M., Touzart, A., Jahn, E., Vick, B., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0278 · Cited by 9
“We tested Pyjacker on two existing datasets with known enhancer hijacking events: 10 AML cell lines and 120 medullo-blastoma samples (29, 30).”
Self-citationPediatric brain tumors: Update of proteome-based studies
Tsangaris, G. T., & Anagnostopoulos, A. K. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.02.016 · Cited by 7
Differential Expression of Genes for Ubiquitin Ligases in Medulloblastoma Subtypes
Vriend, J. P., & TATE, R. B. (2019) · The Cerebellum · doi:10.1007/s12311-019-1009-y · Cited by 7
Development of a prognostic model based on an immunogenomic landscape analysis of medulloblastoma
Guo, Y., Li, S., Huang, P., Zhang, H., & Yu, C. (2021) · Bioscience Reports · doi:10.1042/bsr20202907 · Cited by 6
Holdhof, D., On, J. H., Schoof, M., Göbel, C., & Schüller, U. (2021) · The Cerebellum · doi:10.1007/s12311-020-01219-2 · Cited by 7
Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma
Westphal, M. S., Lee, E., Schadt, E. E., Sholler, G. L. S., & Zhu, J. (2021) · Cancers · doi:10.3390/cancers14010139 · Cited by 6
“The overall survival rates of the four MB subgroups were not significantly different (Supplementary Figure S10), and SHH-MB was the most heterogeneous subgroup among the four MB subgroups [12].”
BackgroundClinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma
Mani, S., Chatterjee, A., Dasgupta, A., Shirsat, N. V., Pawar, A., Epari, S., Sahay, A., Sahu, A., Moiyadi, A. V., Prasad, M., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14040358 · Cited by 6
“…to perform large-scale integrative clustering analysis combining DNA methylation and gene-expression profiling to identify further sub-types within each broad molecular subgroup [24–26] resulting in a consensus definition of 12 subtypes of MB in second-generation molecular subgrouping [27].”
BackgroundChan, G., & Chan, C. M. (2020) · Pediatric Investigation · doi:10.1002/ped4.12211 · Cited by 5
Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1
Paret, C., Lehmann, N., Bender, H. G., Sprang, M., Sommer, C., Cana, D., Seidmann, L., Wingerter, A., Neu, M. A., Malki, K. E., et al. (2021) · Cancers · doi:10.3390/cancers13225838 · Cited by 7
“It is interesting to note that few reported medulloblastoma-specific fusion peptides, such as MLLT6–MRPL45, LCLAT1–ERBB4, ASAP1–WD4HV1 and PTEN– THAP9 [2,14,15] have similar immunogenic potential to the EPC2–GULP1 fusion peptide SAEEITLTI.”
BackgroundInhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
Filipponi, D., Pagnuzzi‐Boncompagni, M., & Pagès, G. (2022) · Cancers · doi:10.3390/cancers14092095 · Cited by 10
Aukema, S., Glaser, S., van den Hout, M. F. C. M., Dahlum, S., Blok, M. J., Hillmer, M., Kolarova, J., Sciot, R., Schott, D. A., Siebert, R., et al. (2022) · Familial Cancer · doi:10.1007/s10689-022-00306-z · Cited by 6
Williams, A. P., Garner, E. F., Stafman, L. L., Aye, J. M., Quinn, C. H., Marayati, R., Stewart, J. E., Atigadda, V. R., Mroczek‐Musulman, E., Moore, B. P., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.003 · Cited by 6
“By 2012, consensus emerged that there are at least four distinct molecular subgroups of MB that differ in their transcriptomes, somatic genetic events, and clinical outcomes [36], and even more recent data have emerged demonstrating that significant molecular heterogeneity exists within the four subgroups [37].”
BackgroundSadowski, M., Kraft, A., Szałaj, P., Wlasnowolski, M., Tang, Z., Ruan, Y., & Plewczyński, D. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/266981 · Cited by 6
Medulloblastoma: novel insights into emerging therapeutic targets
Shaik, S., Maegawa, S., & Gopalakrishnan, V. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1982896 · Cited by 8
Evolution of neurosurgical advances and nuances in medulloblastoma therapy
Rechberger, J. S., Power, E. A., DeCuypere, M. G., & Daniels, D. J. (2023) · Child s Nervous System · doi:10.1007/s00381-023-06239-x · Cited by 5
“Noteworthy, several mutations intersect with those identified in Group 3 MBs, including MCYN and OTX2, underscoring the intricate interplay between these molecular subgroups [59, 64].”
3D genome topology distinguishes molecular subgroups of medulloblastoma
Lee, J. J. Y., Johnston, M. J. G., Farooq, H., Chen, H., Younes, S. T., Suárez, R. A., Zwaig, M., Juretic, N., Weiss, W. A., Ragoussis, J., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.10.003 · Cited by 5
Self-citationTargeting processive transcription for Myc-driven circuitry in medulloblastoma
Sobral, L. M., Walker, F. M., Madhavan, K. P. C., Janko, E., Donthula, S., Danis, E. P., Bompada, P., Balakrishnan, I., Wang, D., Pierce, A. M., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf121 · Cited by 7
Schoof, M., Zheng, T., Sill, M., Imle, R., Cais, A., Altendorf, L., Fürst, A., Hofmann, N., Ernst, K., Vonficht, D., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02419-4 · Cited by 5
“CNAs, involving gains or deletions of large genomic segments, have been described across various cancer entities 7–10 .”
Self-citationMitoxantrone alters CD24/Siglec-10 expression in malignant brain tumor models
Kopecký, J., Pérez, J. E., Jonathan, S., Milos, T., Kwanyuen, P., Biskupiak, J., Visse, E., de Oliveira, K. G., Hugo Talbot, A., Cerezo-Magaña, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-37588-7 · Cited by 6
The landscape of structural variation in pediatric cancer
Greenhalgh, R., Brady, S. W., Yang, W., Flasch, D. A., Edmonson, M. N., Terekhanova, N. V., Liu, Y., Wang, J., Szlachta, K. A., Tian, L., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.012 · Cited by 8
Self-citationGao, J., Zhao, Y., Wang, Z., Liu, F., Chen, X., Mo, J., Jiang, Y., Liu, Y., Tian, P., Li, Y., et al. (2024) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12399 · Cited by 5
“32,33 Whereas the SHH subgroup is easier to model in the laboratory, G3-MB modeling emerged later and remains technically more challenging; however, the call for new therapies aiming at G3 MB remains constantly urgent.”
Self-citationGao, X., Zhuang, Q., Li, Y., Li, G., Huang, Z., Chen, S., Sun, S., Yang, H., Jiang, L., & Mao, Y. Q. (2024) · Advanced Science · doi:10.1002/advs.202309554 · Cited by 4
Unraveling the three-dimensional (3D) genome architecture in Neurodevelopmental Disorders (NDDs)
Carballo-Pacoret, P., Carracedo, Á., & Rodriguez‐Fontenla, C. (2024) · Neurogenetics · doi:10.1007/s10048-024-00774-8 · Cited by 7
“…that deregulation of CTCF due to structural mutations leads to de novo contact formation between super-enhancers and gene promoters, leading to up-regulation especially of PRDM6 (which had not previously been defined as a risk gene in medulloblastoma), through precisely enhancer adoption [68].”
Roy, S., Agnihotri, S., Hallani, S. E., Ernst, W. L., Wald, A. I., Santana‐Santos, L., Hamilton, R. L., Horbinski, C., Wadhwani, N. R., Born, D. E., et al. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz055 · Cited by 5
Chiang, J., Moreira, D. C., Pytel, N. J., Liu, Y., Blackburn, P. R., Shi, Z., Cardenas, M., Wheeler, D. A., & Furtado, L. V. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12815 · Cited by 5
“Of note, none of the reported WNT MBs with SHH pathway alterations harbour CTNNB1 S45 mutations [3, 5, 16].”
BackgroundSelf-citationWang, R., Zhao, L., Wang, S., Zhao, X., Liang, C., Wang, P., & Li, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.989985 · Cited by 5
“…some cancers show an apparent CpG island methylator phenotype (CIMP), of which a critical milestone highlighting the clinical importance of the epigenetic profile of gliomas was the discovery of the glioma CpG island methylation phenotype (G-CIMP) (Northcott et al., 2017; Ogino et al., 2018).”
BackgroundInfluentialClass I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
Vollmer, J., Ecker, J., Hielscher, T., Valinciute, G., Ridinger, J., Jamaladdin, N., Peterziel, H., van Tilburg, C. M., Oehme, I., Witt, O., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04445-w · Cited by 7
“Group 3 and Group 4 tumors show a profound molecular heterogeneity and can be classified into 8 subtypes [4].”
BackgroundMethodInfluentialSelf-citationLi, Q., Jia, Y., Tang, B., Yang, H., Yang, Q., Luo, X., & Pan, Y. (2023) · Biomarkers · doi:10.1080/1354750x.2023.2276670 · Cited by 5
“…eOMes + K167+ unipolar brush cell progenitor cells most likely predispose human species to the development of G4-MB (hendrikse et al. 2022). several studies have investigated the whole-genome landscape of medulloblastoma subtypes (Northcott et al. 2017) to find group-specific drivers and pathways.”
BackgroundChildhood cancer mutagenesis caused by transposase-derived PGBD5
Yamada, M., Keller, R. R., Gutierrez, R. L., Cameron, D., Suzuki, H., Sanghrajka, R. M., Vaynshteyn, J., Gerwin, J. N., Maura, F., Hooper, W. F., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn4649 · Cited by 7
Self-citationPadhye, B. D., Nawaz, U., Hains, P. G., Reddel, R. R., Robinson, P. J., Zhong, Q., & Poulos, R. C. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.30980 · Cited by 6
“Large-scale whole-genome sequencing studies of paediatric cancer 28,51,52 have revealed common features of the molecular landscape.”
BackgroundLee, M. K., Azizgolshani, N., Zhang, Z., Perreard, L., Kolling, F., Nguyen, L., Zanazzi, G. J., Salas, L. A., & Christensen, B. C. (2024) · Nature Communications · doi:10.1038/s41467-024-47943-9 · Cited by 6
Gupta, T., Mani, S., Chatterjee, A., Dasgupta, A., Epari, S., & Chinnaswamy, G. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357807 · Cited by 6
“…to perform large-scale integrative clustering analysis combining DNA methylation and gene-expression profiling to identify further subtypes within each broad molecular subgroup resulting in consensus definition of 12 subtypes of medulloblastoma in second generation molecular subgrouping [49,53–55].”
BackgroundIdentification of tumor rejection antigens and the immunologic landscape of medulloblastoma
Yang, C., Trivedi, V., Dyson, K. A., Gu, T., Candelario, K. M., Yegorov, O., & Mitchell, D. A. (2024) · Genome Medicine · doi:10.1186/s13073-024-01363-y · Cited by 7
“We obtained primarily diagnosed medulloblastoma ( n = 170; 18 WNT, 46 SHH, 41 Group 3, and 65 Group 4) patient-specific mutations and transcriptome data from ICGC (PCAWG, Dec 2020) [12, 36].”
BackgroundMethodInfluentialThe Molecular Basis of Pediatric Brain Tumors: A Review with Clinical Implications
Antoniades, E., Keffes, N., Vorri, S. C., Tsitouras, V., Gkantsinikoudis, N., Tsitsopoulos, P., & Magras, J. (2025) · Cancers · doi:10.3390/cancers17091566 · Cited by 6
Embryonal tumors of the central nervous system
Pagès, M., Masliah‐Planchon, J., & Bourdeaut, F. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000686 · Cited by 6
Ülgen, E., Can, Ö., Bilgüvar, K., Akyerli, C. B., Yüksel, Ş., Danyeli, A. E., Sezerman, O. U., Yakicier, M. C., Pamir, M. N., & Özduman, K. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00904-3 · Cited by 5
Ku, C., Wuputra, K., Kato, K., Pan, J.-B., Li, C.-P., Tsai, M.-H., Noguchi, M., Nakamura, Y., Liu, C., Chan, T., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02424-4 · Cited by 7
“The cancer cohorts originated from the cerebellar granule cells and the precise mapping of the medulloblastomas was reported previously [41, 42].”
BackgroundMolecular profile reveals immune-associated markers of medulloblastoma for different subtypes
Chen, J., Kang, Z., Li, S., Wang, C., Zheng, X., Cai, Z., Pan, L., Chen, F., & Li, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911260 · Cited by 8
Plasma metabolite profiles identify pediatric medulloblastoma and other brain cancer
Shi, Z., Yang, C., Xu, X., Wu, W., Jiang, D., & Yan, D. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04427-3 · Cited by 6
Research progress in molecular pathology markers in medulloblastoma
Zhou, Z., Zhu, B., Meng, Q., Zhang, T., Wu, Y., Yu, R., & Gao, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00126 · Cited by 5
“It was reported that PRDM6 gene expression was markedly upregulated in a subset of group 4 MB patients, due to “enhancer hijacking” induced DNA rearrangement [25].”
BackgroundInfluentialPrecision oncology for children: A primer for paediatricians
Cohen‐Gogo, S., Denburg, A., Villani, A., Thacker, N. H., Egan, G., Rafael, M., Malkin, D. M., & Morgenstern, D. A. (2023) · Paediatrics & Child Health · doi:10.1093/pch/pxac123 · Cited by 10
Kuwahara, Y., Iehara, T., Matsumoto, A., & Okuda, T. (2023) · Cancer Medicine · doi:10.1002/cam4.6255 · Cited by 4
Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma
Chinnam, D., Saraswati, A., Jogunoori, S., Verma, A., Kiran, T., Salunke, P., Gupta, N., Kumar, N., Madan, R., Radotra, B. D., et al. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001143 · Cited by 6
Using evolutionary constraint to define novel candidate driver genes in medulloblastoma
Roy, A., Sakthikumar, S., Kozyrev, S. V., Nordin, J., Pensch, R., Mäkeläinen, S., Pettersson, M. E., Karlsson, E. K., Lindblad‐Toh, K., Forsberg‐Nilsson, K., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300984120 · Cited by 5
“We downloaded variant calls from whole-genome sequencing (WGS) data from the International Cancer Genome Consortium (ICGC) (1, 16) for pilocytic astrocytoma [PA, 89 cases, (Dataset S1) (17)] and medulloblastoma [MB, 146 cases (Dataset S2)] (16).”
InfluentialRadiotherapeutic management of brain tumours during the COVID-19 pandemic
Balakrishnan, R., Sebastian, P., Rajkrishna, B., Venkatasai, J., & Backianathan, S. (2020) · Journal of Radiotherapy in Practice · doi:10.1017/s1460396920000394 · Cited by 5
High-throughput sequencing technologies for cancer genomics
Garima, G., Dhanawat, M., Wilson, K., & Chaubey, P. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.02.018 · Cited by 6
Aberrant histone modifications in pediatric brain tumors
Hamanishi, E. T., Dang, D., & Venneti, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1587157 · Cited by 4
Han, B., Wang, Y., Yue, S., Zhang, Y.-H., Kuang, L., Gao, B., Wang, Y., Zhang, Z., Pu, X., Wang, X.-F., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176044 · Cited by 5
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.